Clinical comprehensive evaluation of Xiaoer Feire Kechuan Oral Liquid in treatment of acute bronchitis in children(syndrome of wind-heat invading lung)
Objective To comprehensively evaluate the clinical application value of Xiaoer Feire Kechuan Oral Liquid(FRKC)in the treatment of acute bronchitis(syndrome of wind-heat invading lung),so as to provide evidence for clinical rational use and regulatory decision-making.Method Based on literature,relevant data platform,clinical investigation and other information,evidence-based medicine,pharmacoeconomics,clinical investigation and other qualitative and quantitative methods were adopted to focus on the six dimensions of safety,effectiveness,economy,suitability,innovation,and accessibility.According to the clinical comprehensive evaluation technology system of children's proprietary Chinese medicine based on multi-criteria decision analysis,the clinical comprehensive evaluation of FRKC was carried out.Result(1)Safety:FRKC does not reflect safety risks in terms of prescription,non-clinical safety,quality supervision,etc.In terms of clinical safety,no serious adverse reactions have been found,and the incidence of adverse reactions is generally low,the degree is mild and short.Overall safety is good and controllable.(2)Effectiveness:Meta-analysis showed that the total effective rate of FRKC combined with conventional western medicine was better than that of conventional Western medicine alone in treating acute bronchitis in children.Network meta-analysis of similar varieties showed that this product ranked first in terms of cough disappearance time,fever reduction time and rales disappearance time.The results of clinical investigation showed that doctors and patients recognized the efficacy of this product in the treatment of acute bronchitis in children.(3)Economy:Pharmacoeconomic studies showed that FRKC combined with conventional treatment has more cost-effectiveness advantages.(4)Suitability:The contents of the FRKC manual are complete and updated in a timely manner,the dosage form and taste are acceptable to children,and the transportation and storage are convenient,which can meet the whole packaging of medicine for all ages,and has good suitability in terms of drug information and drug use.(5)Innovation:FRKC is the fourth new drug of Chinese medicine.Clinical research and guidelines and consensus recommend it for the treatment of influenza,bronchiolitis,viral pneumonia,bronchoppneumonia,mycoplasma pneumonia,chronic cough,urticaria,etc.,with good spillover effect.(6)Accessibility:FRKC has a wide sales range and a high market share.The cost of treatment is relatively low in the proportion of household disposable income,does not contain endangered and expensive fine herbs,and has good accessibility and affordability.Conclusion Based on six dimensions of evidence,the clinical value score of FRKC was 75.578 points by using the clinical comprehensive evaluation tool of children's proprietary Chinese medicine.It is indicated that it has good clinical value in the treatment of pediatric bronchitis(syndrome of wind-heat invading lung),and the evaluation results can provide evidence-based reference for clinical rational drug use and drug decision-making.
NETL
NSTL
万方数据
